Key Points
- Vir Biotechnology director Janet Napolitano sold 3,200 shares on June 1 at an average price of $9.45, totaling about $30,240. The sale reduced her holdings by 13.11% and was made under a pre-arranged Rule 10b5-1 trading plan.
- The stock was trading below its recent average, opening at $8.74 versus a 50-day moving average of $9.49, while remaining above its 200-day average of $7.96. Vir Biotechnology has a market value of about $1.47 billion and a 52-week range of $4.16 to $11.66.
- Recent earnings were weak, with the company reporting a quarterly loss of $0.85 per share versus expectations of a near break-even result and missing revenue estimates by a wide margin. Analysts currently view the stock as a Moderate Buy with an average price target of $20.25.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director owned 21,216 shares in the company, valued at $200,491.20. This trade represents a 13.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vir Biotechnology Stock Performance
VIR opened at $8.74 on Wednesday. The business's 50-day simple moving average is $9.49 and its 200-day simple moving average is $7.96. Vir Biotechnology, Inc. has a one year low of $4.16 and a one year high of $11.66. The stock has a market capitalization of $1.47 billion, a P/E ratio of -2.79 and a beta of 1.65.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.84). Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The firm had revenue of ($0.03) million for the quarter, compared to analyst estimates of $55.49 million. During the same quarter last year, the firm posted ($0.88) EPS. On average, equities research analysts forecast that Vir Biotechnology, Inc. will post -1.75 EPS for the current fiscal year.
Hedge Funds Weigh In On Vir Biotechnology
Several institutional investors have recently added to or reduced their stakes in VIR. AQR Capital Management LLC increased its position in Vir Biotechnology by 2,088.4% in the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company's stock valued at $1,739,000 after acquiring an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Vir Biotechnology in the 1st quarter valued at approximately $359,000. Goldman Sachs Group Inc. boosted its holdings in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP boosted its holdings in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company's stock valued at $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth boosted its holdings in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company's stock valued at $125,000 after purchasing an additional 2,566 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on VIR. Barclays boosted their price target on Vir Biotechnology from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Tuesday, February 24th. Evercore restated an "outperform" rating and issued a $18.00 price target on shares of Vir Biotechnology in a research report on Tuesday, February 24th. HC Wainwright boosted their price target on Vir Biotechnology from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Morgan Stanley set a $23.00 price target on Vir Biotechnology in a research report on Friday, May 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $20.25.
Check Out Our Latest Stock Report on Vir Biotechnology
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
